Display Settings:

Format

Send to:

Choose Destination
    Prostate. 2012 May 1;72(6):587-91. doi: 10.1002/pros.21465. Epub 2011 Jul 27.

    Development of a castrate resistant transplant tumor model of prostate cancer.

    Source

    Roswell Park Cancer Institute, Genitourinary Program, Grace Cancer Drug Center, Buffalo, New York, USA.

    Abstract

    BACKGROUND:

    Currently, limited mouse models that mimic the clinical course of castrate resistant prostate development currently exist. Such mouse models are urgently required to conduct pre-clinical studies to assist in the understanding of disease progression and the development of rational therapeutic strategies to treat castrate resistant prostate cancer.

    METHODS:

    Wild type intact FVB male mice were injected by subcutaneous injection with Myc-CaP cells to establish androgen sensitive Myc-CaP tumors. Tumor bearing mice were castrated and resulting tumors serially passaged in pre-castrated FVB male mice to produce a bone fide Myc-CaP castrate resistant tumor.

    RESULTS:

    Immunohistochemical analysis revealed that initial androgen sensitive Myc-CaP tumors had strong nuclear transcriptional active androgen receptor expression, as indicated by marked c-MYC staining and were highly proliferative. Castration of tumor bearing animals resulted in cytoplasmic relocation of androgen receptor concurrent with loss of transcriptional activity and tumor proliferation. Serial passaging of castrate refractory Myc-CaP in pre-castrated male FVB mice resulted in the development of a bona fide castrate resistant Myc-CaP tumor which pheno-copied the original androgen sensitive parental Myc-CaP tumor.

    CONCLUSIONS:

    Developing a murine castrate transplant resistant tumor model that mimics the clinical course of human castrate resistant prostate cancer will create better opportunities to understand the development of castrate resistant prostate cancer and also allow for more rapid pre-clinical studies to stratify rational novel therapies for this lethal form of prostate cancer.

    Copyright © 2011 Wiley Periodicals, Inc.

    PMID:
    21796655
    [PubMed - in process]
    PMCID:
    PMC3298731
    Free PMC Article

    Images from this publication.See all images (3) Free text

    Fig. 1
    Fig. 3
    Fig. 2

      Supplemental Content

      Icon for John Wiley & Sons, Inc. Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk